Year of Preparations for the Next Fifty Years’ will contribute to country’s development process
In 2020, the UAE’s achievements, most notably the launch of the Hope Probe to Mars and the operation of Unit 1 of the Barakah Nuclear Power Plant, have proven that the “Year of Preparations for the Next Fifty Years” will significantly contribute to the country’s development process.
The Barakah Nuclear Power Plant also highlights the UAE’s efforts to build the capacities of national cadres in this sector. Nearly 244 employees work for the Federal Authority for Nuclear Regulation, FANR, with 67 percent being Emiratis, of which 45 percent are in leading and managerial positions. Women also account for over 40 percent of the Authority’s employees.
Once all four units of the plant are commercially operating, the UAE’s Barakah Nuclear Energy Plant will produce up to 25 percent of the country’s electricity requirements while in parallel preventing the release of 21 million tons of carbon emissions each year.
In May, a patent was granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells. The treatment was developed by a team of doctors and researchers at the Abu Dhabi Stem Cell Center, ADSCC, and involves extracting stem cells from the patient’s own blood and reintroducing them after activating them.
QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company, IHC, announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale.
The technology will reinforce the UAE’s position as a hub of research and innovation, as scientists around the world scramble to devise a faster method of testing for patients suspected to have been infected with the coronavirus and potentially identifying carriers before they become infectious.
The first World Health Organisation, WHO, enlisted global clinical Phase III trial of Sinopharm CNBG’s inactivated vaccine to combat COVID-19 started in Abu Dhabi.
The world’s first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the world’s sixth-largest vaccine manufacturer, ranked 169th on the Fortune Global 500 list of 2018.
The trials are being operated by health practitioners from Abu Dhabi Health Services, SEHA, who are providing facilities at five of their clinics in Abu Dhabi and Al Ain in addition to a mobile clinic to ensure the trials are readily accessible to volunteers participating in the programme.
